Optimind Pharma Transitions to Semi-Annual Financial Reporting Under CSA’s Coordinated Blanket Order 51-933

Shift to Semi-Annual Reporting Under CSA Pilot Program

Optimind Pharma has elected to participate in the Canadian Securities Administrators’ pilot program, transitioning from quarterly to semi-annual financial reporting. This change takes effect immediately, with the first quarter ending May 31, 2026, no longer requiring a quarterly interim report. Normally, this report would have been due by July 30, 2026, but under CBO 51-933 exemptions, the company defers this requirement.

The transition is voluntary and contingent on the company’s continued eligibility within the pilot program. Optimind Pharma will persist in filing audited annual financial statements and management’s discussion and analysis (MD&A), alongside six-month interim financial statements and related MD&A, per applicable securities regulations. The company’s fiscal year end remains February 28.

Enhancing Operational Efficiency and Reducing Costs

By adopting semi-annual reporting, Optimind Pharma aims to lessen the administrative and financial pressures linked to quarterly interim filings. Management expects this change to free up resources and time to focus on advancing core business strategies. The streamlined disclosure requirements are designed to benefit venture issuers that meet the Canadian Securities Administrators’ eligibility criteria.

The CBO 51-933 pilot program was specifically created to help eligible venture issuers manage reporting and regulatory expenses. Optimind Pharma’s participation reflects its assessment that the operational efficiencies gained will support enhanced focus on business growth and strategic initiatives.

Regulatory Framework and Eligibility Criteria

Under Coordinated Blanket Order 51-933, eligible venture issuers may voluntarily switch from quarterly to semi-annual financial reporting. For Optimind Pharma, this means no longer filing interim financial reports and MD&A for the first and third fiscal quarters. However, the company remains fully subject to continuous disclosure requirements, including prompt material change reporting.

As a reporting issuer in Alberta, British Columbia, and Ontario, and listed on the Canadian Securities Exchange, Optimind Pharma qualifies for CBO 51-933. Continued reliance on these exemptions depends on ongoing eligibility and the availability of the pilot program. Should eligibility or program status change, the company’s reporting obligations could revert to quarterly filings.

Financial Reporting Schedule and Deadlines

Under the semi-annual framework, Optimind Pharma’s next financial report will cover the six-month interim period ending August 31, 2026, filed according to securities law timelines. This will be the first semi-annual interim report under the new structure. Subsequently, the company will file audited annual financial statements for the fiscal year ending February 28, 2027.

The fiscal year ending February 28 establishes a reporting calendar where semi-annual interim reports for periods ending August 31 will be submitted within standard deadlines. Annual audited statements will continue to be filed post fiscal year-end, with no change to annual reporting requirements.

Maintaining Compliance and Continuous Disclosure

Despite fewer quarterly reports, Optimind Pharma remains fully compliant with all continuous disclosure obligations mandated for reporting issuers on the Canadian Securities Exchange. The company will continue timely reporting of material changes in accordance with securities laws. The semi-annual reporting change affects only interim financial disclosure frequency and does not alter broader compliance responsibilities.

Management disclosure obligations, material change notifications, insider trading regulations, and other continuous disclosure requirements remain fully enforced and will be adhered to as required by law.

Program Continuity and Contingency Considerations

Optimind Pharma plans to maintain semi-annual reporting subject to the ongoing availability of CBO 51-933 and its eligibility. As the pilot program is temporary, regulatory decisions by the Canadian Securities Administrators could impact its continuation. The company’s ability to sustain semi-annual reporting depends on regulatory factors and its ongoing compliance with eligibility criteria.

The announcement does not specify contingency plans if exemptions become unavailable or eligibility is lost. Forward-looking statements note that maintaining this reporting structure assumes continued program access and eligibility. Investors should monitor CSA updates regarding CBO 51-933 that may affect Optimind Pharma’s reporting obligations.

About Optimind Pharma and Its Market Listing

Optimind Pharma Corp. is a reporting issuer in Alberta, British Columbia, and Ontario, and trades on the Canadian Securities Exchange under the ticker "OMND." Its status as a CSE-listed venture issuer qualifies it for participation in the CBO 51-933 pilot program.

Operating as a venture issuer, Optimind Pharma functions within a regulatory framework tailored for smaller public companies raising capital in Canada. The semi-annual reporting exemption is designed to alleviate resource and administrative burdens typical for companies at this stage.

Forward-Looking Statements and Risk Factors

The announcement contains forward-looking information about the company’s shift to semi-annual reporting, reliance on CBO 51-933 exemptions, expected administrative savings, and future reporting timelines. These statements rest on assumptions including continued eligibility, exemption availability, and successful execution of business plans.

Actual results may differ materially due to risks and uncertainties described in the company’s latest MD&A, available on SEDAR+ at www.sedarplus.ca under Optimind Pharma’s profile. The company advises investors to exercise caution and conduct their own risk assessments regarding forward-looking statements.

Investor Guidance and Access to Filings

Investors should note that quarterly financial updates will be less frequent following the transition to semi-annual reporting. While continuous disclosure and material change reporting remain in effect, standardized quarterly performance reports will no longer be available.

All Optimind Pharma financial disclosures and regulatory filings continue to be accessible via SEDAR+ (www.sedarplus.ca), the Canadian Securities Administrators’ electronic document system. Investors can track semi-annual interim reports, annual audited statements, and related filings through this platform. The company’s Canadian Securities Exchange listing also provides trading data and regulatory updates.